Combination Chemotherapy Alone Should Be Used in the Treatment of Patients With Stage IV EGFR-Mutant NSCLC Whose Disease Has Progressed on All Available Tyrosine Kinase Inhibitors

The discovery of the driver gene EGFR and the precision treatment of this target have been a revolution in the treatment of NSCLC. The EGFR tyrosine kinase inhibitor (TKI), osimertinib, has become a standard treatment for patients with advanced or resected NSCLC harboring EGFR mutations. In the FLAURA study, osimertinib was administered as first-line treatment in advanced disease, and compared with first-generation drugs, it significantly improved the duration of response (from 8.5 to 17.2 mo), progression-free survival (from 10.2 to 18.9 mo), and overall survival (OS) (from 31.8 to 38.6 mo).